A new trading day began on Friday, with Janux Therapeutics Inc (NASDAQ: JANX) stock price down -3.12% from the previous day of trading, before settling in for the closing price of $37.17. JANX’s price has ranged from $10.06 to $71.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 32.66% over the past five years. Meanwhile, its annual earnings per share averaged -11.44%. With a float of $48.09 million, this company’s outstanding shares have now reached $52.34 million.
Let’s look at the performance matrix of the company that is accounted for 64 employees. In terms of profitability, gross margin is 87.98%, operating margin of -658.76%, and the pretax margin is -463.91%.
Janux Therapeutics Inc (JANX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Janux Therapeutics Inc is 16.80%, while institutional ownership is 108.82%. The most recent insider transaction that took place on Feb 03 ’25, was worth 140,999. In this transaction Chief Business Officer of this company sold 3,334 shares at a rate of $42.29, taking the stock ownership to the 82,139 shares. Before that another transaction happened on Feb 03 ’25, when Company’s Officer proposed sale 3,334 for $43.48, making the entire transaction worth $144,962.
Janux Therapeutics Inc (JANX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -24.84% during the next five years compared to -92.62% drop over the previous five years of trading.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Here are Janux Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 38.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 159.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.98 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc (NASDAQ: JANX) saw its 5-day average volume 0.71 million, a negative change from its year-to-date volume of 1.03 million. As of the previous 9 days, the stock’s Stochastic %D was 19.79%. Additionally, its Average True Range was 2.79.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 1.63%, which indicates a significant decrease from 5.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.57% in the past 14 days, which was lower than the 89.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.72, while its 200-day Moving Average is $46.95. Nevertheless, the first resistance level for the watch stands at $37.78 in the near term. At $39.54, the stock is likely to face the second major resistance level. The third major resistance level sits at $40.67. If the price goes on to break the first support level at $34.89, it is likely to go to the next support level at $33.76. The third support level lies at $32.00 if the price breaches the second support level.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
With a market capitalization of 2.08 billion, the company has a total of 52,482K Shares Outstanding. Currently, annual sales are 8,080 K while annual income is -58,290 K. The company’s previous quarter sales were 440 K while its latest quarter income was -28,060 K.
